BATTALION
Single-arm multicenter Phase II trial to investigate the efficacy of Botensilimab and Balstilimab in combination with gemcitabine/cisplatin for previously untreated patients with advanced or metastatic biliary tract cancer
(CORAL-1, AIO HB XXXX) (BAlstilimab boTensilimab in the TreAtment of choLangIOcellular carcinoma)
II
interventionell
National
Status: In Vorbereitung
Zeitraum
2024
2026
Zentren
15
Zentren gesucht
Patienten
40
20.09.2023
Klinische Settings
IV
1st line
palliativ
Identifier
AIO-HEP-0123
Kontakt
Leitung
Prof. Dr. med. Dominik Paul Modest
Ansprechpartner*in
Prof. Dr. med. Dominik Paul Modest
E-Mail dominik.modest@charite.de